Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 3/20 | 0.42 |
| ▸ | FNTB | P49356 | 3/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538056 | 1.00 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| Hydrochloric Acid SCHEMBL28446971 | 0.98 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| Hydrochloric Acid SCHEMBL28446972 | 0.98 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL29350823 | 0.94 | MMP2 (0.41) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL30052506 | 0.88 | TSHR (0.47) | LMNAFNTAFNTBPGGT1BPTGS1 | |
| SCHEMBL30052913 | 0.88 | METAP2 (0.43) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL8000185 | 0.87 | FNTA (0.48) | FNTAFNTBPGGT1BPTGS1GSTK1 | |
| SCHEMBL8000193 | 0.87 | FNTA (0.48) | FNTAFNTBPGGT1BPTGS1GSTK1 | |
| SCHEMBL30052468 | 0.85 | FNTA (0.43) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL30590002 | 0.85 | PTGS1 (0.42) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724610-A2 | HIGH THROUGHPUT SCREEN FOR GENETIC VARIANTS ASSOCIATED WITH SHORT STATURE | BioMarin Pharmaceutical Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4013453-B1 | HYDROPHOBIC PEPTIDE SALTS FOR EXTENDED RELEASE COMPOSITIONS | BIOMARIN PHARM INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-12514906-B2 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | BIOMARIN PHARMACEUTICAL INC. (US) | 2026-01-06 | — | — | US | claimed |
| US-20250170217-A1 | C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA IN CHILDREN | BIOMARIN PHARMACEUTICAL INC. | 2025-05-29 | — | — | US | claimed |
| WO-2025076498-A1 | TREATMENT OF OSTEOGENESIS IMPERFECTA WITH C-TYPE NATRIURETIC PEPTIDE AND ANALOGS THEREOF | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-12233106-B2 | C-type natriuretic peptide variants to treat skeletal dysplasia in children | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-25 | — | — | US | claimed |
| US-12214015-B2 | Use of c-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-04 | — | — | US | claimed |
| US-20250032576-A1 | CNP Therapy | BIOMARIN PHARMACEUTICAL INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024254405-A2 | HIGH THROUGHPUT SCREEN FOR GENETIC VARIANTS ASSOCIATED WITH SHORT STATURE | BIOMARIN PHARMACEUTICAL INC. (US) | 2024-12-12 | — | — | WO | claimed |
| CN-119104653-A | Method for detecting impurities in compound amino acid injection | 四川太平洋药业有限责任公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2023283657-A1 | C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA IN CHILDREN | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-01-12 | — | — | WO | claimed |
| EP-4019038-A2 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BioMarin Pharmaceutical Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| CN-108472336-B | Use of C-type natriuretic peptide variants for the treatment of skeletal dysplasia | 生物马林药物股份有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20220160836-A1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARMACEUTICAL INC. | 2022-05-26 | — | — | US | claimed |
| US-20160374380-A1 | SALTY TASTE ENHANCER | T. HASEGAWA CO., LTD. (JP) | 2016-12-29 | — | — | US | claimed |
| EP-0357784-B1 | A FEED COMPOSITION FOR CULTURING FISHES AND SHELLFISHES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-09-02 | — | — | EP | claimed |
| EP-0357784-A1 | A FEED COMPOSITION FOR CULTURING FISHES AND SHELLFISHES. | KYOWA HAKKO KOGYO KK (JP) | 1990-03-14 | — | — | EP | claimed |
| WO-1989006497-A1 | A FEED COMPOSITION FOR CULTURING FISHES AND SHELLFISHES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-07-27 | — | — | WO | claimed |
| US-4095000-A | AMINO ACIDS AND DERIVATIVES, POLYHYDROXY COMPOUNDS, NUTRIENTS, HYDROLYSIS | Brenner, Max (CH) | 1978-06-13 | — | — | US | claimed |
| US-3959519-A | Fortification of food materials with a methionine source | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032576-A1 | CNP Therapy | CNP, NPPA, NPR1 | ALDH1A1 4498/4885LMNA 897/4885MAPT 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.